ASCETTS (R21): Early-stage platform technologies for translational therapeutics (no clinical trials)
NCATS ASCETTS R21 supports high-risk, high-reward, disease-agnostic platform technologies aimed at removing bottlenecks in therapeutic development; clinical trials are not allowed. The award funds early-stage proof-of-concept and prototyping (often with little preliminary data) over a two-year period to advance technologies toward NIH or industry follow-on support and eventual commercializatio…
Therapeutic development is a costly, complex, and time-consuming process. The average length of time from target discovery to approval of a new drug is 10-15 years, and the cost per successful drug can be $1 billion or more. Thus, while humans suffer thousands of diseases, only hundreds of treat…
Funding Source
Awards & funding
Eligibility
Foreign/Non-domestic entities: Non-domestic (non-U.S.) entities (Foreign Organizations) are NOT eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are NOT eligible to apply as applicant organizations. Foreign components, as defined in the NIH Grants Policy Statement, are…
Dates
Supporting links
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers